Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Eiger BioPharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Eiger BioPharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Eiger BioPharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Eiger BioPharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Eiger BioPharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Eiger BioPharmaceuticals Inc, Pharmaceuticals & Healthcare, Deal Details 12
Asset Purchase 12
Eiger BioPharma Acquires Assets and Rights to exendin 9-39 from Tracey McLaughlin and Colleen Craig 12
Venture Financing 13
Eiger BioPharma Raises USD3 Million in Venture Financing 13
Celladon Raises USD3 Million in Venture Financing 14
Eiger BioPharma Raises USD6 Million in Venture Financing 15
Eiger Biopharma Raises US$1 Million In Third Tranche Of Series A Financing 16
Partnerships 17
Eiger BioPharma Enters into Collaboration Agreement with Progeria Research 17
Merger 18
Eiger BioPharma Merges with Celladon 18
Licensing Agreements 20
Eiger BioPharmaceuticals Enters into Licensing Agreement with Bristol-Myers Squibb 20
Eiger BioPharma Enters into Licensing Agreement with Stanford University for Post-Bariatric Surgical Hypoglycemia 21
Eiger BioPharma Enters into Licensing Agreement with Stanford University 22
Eiger BioPharma Enters into Licensing Agreement with Stanford University for Pulmonary Arterial Hypertension 23
Eiger BioPharma Enters into Licensing Agreement with Nippon Kayaku 24
Eiger BioPharma Enters into Licensing Agreement with Janssen Pharma for Tipifarnib 25
Equity Offering 26
Eiger BioPharma Prices Public Offering of Shares for USD40 Million 26
Eiger BioPharma Raises USD18.5 Million in Public Offering of Shares 28
Eiger BioPharma Raises USD20 Million in Public Offering of Shares 30
Eiger BioPharma Plans to Raise up to USD25 Million in Public Offering of Shares 32
Eiger BioPharma Raises USD39.5 Million in Private Placement of Shares 33
Asset Transactions 35
Eiger BioPharma Sells Mydicar to Theragene Pharma 35
Eiger BioPharmaceuticals Inc – Key Competitors 36
Eiger BioPharmaceuticals Inc – Key Employees 37
Eiger BioPharmaceuticals Inc – Locations And Subsidiaries 38
Head Office 38
Other Locations & Subsidiaries 38
Recent Developments 39
Financial Announcements 39
Aug 10, 2018: Eiger Biopharmaceuticals announces second quarter 2018 financial results 39
May 11, 2018: Eiger BioPharmaceuticals Reports First Quarter 2018 Financial Results 40
Mar 12, 2018: Eiger BioPharmaceuticals Announces Fourth Quarter and Full Year 2017 Financial Results 41
Nov 09, 2017: Eiger BioPharmaceuticals Reports Third Quarter 2017 Financial Results 42
Aug 14, 2017: Eiger BioPharmaceuticals Reports Second Quarter 2017 Financial Results 44
May 12, 2017: Eiger BioPharmaceuticals Reports First Quarter 2017 Financial Results 45
Mar 23, 2017: Eiger BioPharmaceuticals Reports Fourth Quarter and Full Year 2016 Financial Results 47
Corporate Communications 49
Jan 08, 2018: Eiger BioPharmaceuticals Announces Appointment of Commercial Operations Industry Veteran Eldon Mayer to its Board of Directors 49
Jan 03, 2018: Eiger BioPharmaceuticals Appoints David Apelian, MD, PhD, MBA Chief Operating Officer and Executive Medical Officer 50
Sep 18, 2017: Eiger Announces Appointment of Biopharmaceutical Industry Veteran Evan Loh, MD to its Board of Directors 51
Jun 14, 2017: Eiger Announces Appointment of Biopharmaceutical Industry Veteran David Apelian, MD, PhD, MBA to its Board of Directors 52
Apr 18, 2017: Eiger BioPharmaceuticals appoints new lead for development of PBH treatment 53
Product News 54
04/18/2017: Eiger Announces Industry Veteran Lisa Porter, M.D. to Lead Development of Exendin 9-39 for the Treatment of Post-Bariatric Hypoglycemia 54
Product Approvals 55
Sep 05, 2017: Eiger Announces FDA Orphan Drug Designation Granted for Pegylated Interferon Lambda in Hepatitis Delta Virus Infection 55
Jul 27, 2017: Eiger Announces FDA Fast Track Designation Granted for Pegylated Interferon Lambda in Hepatitis Delta Virus Infection 56
May 03, 2017: Eiger Announces U.S. IND Filing of Pegylated Interferon Lambda for Hepatitis Delta Virus Infection – LIMT HDV: Lambda Interferon MonoTherapy in HDV Study Enrolling 57
Clinical Trials 58
Aug 14, 2018: Eiger BioPharmaceuticals completes enrolment in Prevent trial 58
Mar 26, 2018: Eiger Announces First Patient Dosed in Phase 2 PREVENT Study of Exendin 9-39 in Patients Suffering from Post-Bariatric Hypoglycemia 59
Oct 23, 2017: Eiger Announces Positive Phase 2 Interim 24-Week Data with Pegylated Interferon Lambda in Hepatitis Delta Virus Infection at the American Association for the Study of Liver Diseases Meeting 60
Oct 02, 2017: Eiger Announces Presentation on Lambda at the American Association for the Study of Liver Diseases Meeting 61
Jul 24, 2017: Eiger Completes Enrollment in Phase 2 LIMT HDV Study of Pegylated Interferon Lambda in Hepatitis Delta Virus Infection 62
Jun 12, 2017: Eiger Reports Additional Positive Phase 2 Results from Multiple-Ascending Dose Study of Exendin 9-39 in Post-Bariatric Hypoglycemia Patients at American Diabetes Association Meeting in San Diego 63
Jun 06, 2017: Eiger Completes Enrollment in Phase 2 Multiple-Ascending Dose Study of Exendin 9-39 in Post-Bariatric Hypoglycemia Patients 65
Appendix 66
Methodology 66
About GlobalData 66
Contact Us 66
Disclaimer 66
Eiger BioPharmaceuticals Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Eiger BioPharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Eiger BioPharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Eiger BioPharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Eiger BioPharmaceuticals Inc, Deals By Therapy Area, 2012 to YTD 2018 9
Eiger BioPharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Eiger BioPharma Acquires Assets and Rights to exendin 9-39 from Tracey McLaughlin and Colleen Craig 12
Eiger BioPharma Raises USD3 Million in Venture Financing 13
Celladon Raises USD3 Million in Venture Financing 14
Eiger BioPharma Raises USD6 Million in Venture Financing 15
Eiger Biopharma Raises US$1 Million In Third Tranche Of Series A Financing 16
Eiger BioPharma Enters into Collaboration Agreement with Progeria Research 17
Eiger BioPharma Merges with Celladon 18
Eiger BioPharmaceuticals Enters into Licensing Agreement with Bristol-Myers Squibb 20
Eiger BioPharma Enters into Licensing Agreement with Stanford University for Post-Bariatric Surgical Hypoglycemia 21
Eiger BioPharma Enters into Licensing Agreement with Stanford University 22
Eiger BioPharma Enters into Licensing Agreement with Stanford University for Pulmonary Arterial Hypertension 23
Eiger BioPharma Enters into Licensing Agreement with Nippon Kayaku 24
Eiger BioPharma Enters into Licensing Agreement with Janssen Pharma for Tipifarnib 25
Eiger BioPharma Prices Public Offering of Shares for USD40 Million 26
Eiger BioPharma Raises USD18.5 Million in Public Offering of Shares 28
Eiger BioPharma Raises USD20 Million in Public Offering of Shares 30
Eiger BioPharma Plans to Raise up to USD25 Million in Public Offering of Shares 32
Eiger BioPharma Raises USD39.5 Million in Private Placement of Shares 33
Eiger BioPharma Sells Mydicar to Theragene Pharma 35
Eiger BioPharmaceuticals Inc, Key Competitors 36
Eiger BioPharmaceuticals Inc, Key Employees 37
Eiger BioPharmaceuticals Inc, Subsidiaries 38
List of Figures
Eiger BioPharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Eiger BioPharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Eiger BioPharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Eiger BioPharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Eiger BioPharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Eiger BioPharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
Eiger BioPharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Eiger BioPharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
【免責事項】
http://www.globalresearch.jp/disclaimer